<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941912</url>
  </required_header>
  <id_info>
    <org_study_id>EVRL</org_study_id>
    <nct_id>NCT03941912</nct_id>
  </id_info>
  <brief_title>The Effect of Low Level Laser Therapy on Neck and Shoulder Pain</brief_title>
  <official_title>An Evaluation of the Erchonia EVRL on Neck and Shoulder Pain of Musculoskeletal Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erchonia Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erchonia Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to see if applying red and violet low level laser light to the neck and&#xD;
      shoulders can help to reduce pain in the neck and shoulders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is the goal of the current study to demonstrate non-inferiority in efficacy of the&#xD;
      Erchonia® EVRL when used in simultaneous dual diode mode (both the red (640 nano-meter (nm))&#xD;
      and violet (405 nm) diodes activated simultaneously) compared to its use with the red diode&#xD;
      only activated, for adjunctive use in providing temporary relief of minor chronic neck and&#xD;
      shoulder pain of musculoskeletal origin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">March 10, 2019</completion_date>
  <primary_completion_date type="Actual">March 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)</measure>
    <time_frame>one day</time_frame>
    <description>The Visual Analog Scale (VAS) from one day, baseline to endpoint measurement (following 13-minute treatment administration) is calculated for each subject. Individual subject success is defined as a 30% or greater change in VAS pain scores across the evaluation period. A negative (-) percent change indicates a decrease in pain level and is positive for individual subject success. A positive (+) percent change indicates an increase in pain level and is negative for individual subject success.&#xD;
Overall study success criteria is defined as at least 65%±5% (percentage of subjects) meeting the study individual success criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Erchonia EVRL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>635 nanometers (nm) and 405 nm dual-diode laser application</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erchonia EVRL</intervention_name>
    <description>Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.</description>
    <arm_group_label>Erchonia EVRL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject presents with one or more of chronic neck or shoulder pain.&#xD;
&#xD;
          -  Subject is diagnosed with of one or more of osteoarthritis, chronic muscle spasms or&#xD;
             cervical and thoracic spine sprain strain.&#xD;
&#xD;
          -  Pain is chronic, having persisted for longer than the past 30 days&#xD;
&#xD;
          -  Self-reported Pain rating on the 0-100 Visual Analog Scale (VAS) of 50 or greater.&#xD;
&#xD;
          -  Willing and able to refrain from consuming any over-the-counter and/or prescription&#xD;
             medication(s) and/or herbal supplements intended for the relief of pain and/or&#xD;
             inflammation, including muscle relaxants throughout the course of study participation.&#xD;
&#xD;
          -  Willing and able to refrain from engaging in any non-study procedure therapies&#xD;
             throughout the course of study participation, including conventional therapies such as&#xD;
             physical therapy, occupational therapy and hot or cold packs, as well as alternative&#xD;
             therapies such as chiropractic care and acupuncture&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current active chronic pain disease: such as chronic fatigue syndrome and fibromyalgia&#xD;
&#xD;
          -  Use of analgesics or muscle relaxants within 7 days prior to study procedure&#xD;
             administration.&#xD;
&#xD;
          -  Use of systemic corticosteroid therapy (inhaled and topical corticosteroids&#xD;
             permitted), narcotics or Botulinum toxin (Botox®) injection in the neck/shoulder&#xD;
             region within 30 days prior to study procedure administration.&#xD;
&#xD;
          -  Active cancer or treatment for cancer within the last 6 months.&#xD;
&#xD;
          -  Unstable cardiac disease, such as recent cardiac arrhythmia, congestive heart failure&#xD;
             or myocardial infarction.&#xD;
&#xD;
          -  Prior surgery to the neck/shoulder region.&#xD;
&#xD;
          -  Known herniated disc injury.&#xD;
&#xD;
          -  Active infection, would or other external trauma to the areas to be treated with the&#xD;
             laser Medical, physical or other contraindications for or sensitivity to light&#xD;
             therapy.&#xD;
&#xD;
          -  Serious known mental health illness such as dementia or schizophrenia; psychiatric&#xD;
             hospitalization in the past two years.&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  Participation in a research study within the past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Silverman, DC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Test Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comey Chiropractic Clinic</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York ChiroCare</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <results_first_submitted>January 25, 2020</results_first_submitted>
  <results_first_submitted_qc>October 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2021</results_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03941912/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erchonia EVRL</title>
          <description>635 nanometers (nm) and 405 nm dual-diode laser application&#xD;
Erchonia EVRL: Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erchonia EVRL</title>
          <description>635 nanometers (nm) and 405 nm dual-diode laser application&#xD;
Erchonia EVRL: Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.07" spread="14.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Neck and Shoulder Pain</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.58" spread="110.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)</title>
        <description>The Visual Analog Scale (VAS) from one day, baseline to endpoint measurement (following 13-minute treatment administration) is calculated for each subject. Individual subject success is defined as a 30% or greater change in VAS pain scores across the evaluation period. A negative (-) percent change indicates a decrease in pain level and is positive for individual subject success. A positive (+) percent change indicates an increase in pain level and is negative for individual subject success.&#xD;
Overall study success criteria is defined as at least 65%±5% (percentage of subjects) meeting the study individual success criteria.</description>
        <time_frame>one day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erchonia EVRL</title>
            <description>635 nanometers (nm) and 405 nm dual-diode laser application&#xD;
Erchonia EVRL: Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)</title>
          <description>The Visual Analog Scale (VAS) from one day, baseline to endpoint measurement (following 13-minute treatment administration) is calculated for each subject. Individual subject success is defined as a 30% or greater change in VAS pain scores across the evaluation period. A negative (-) percent change indicates a decrease in pain level and is positive for individual subject success. A positive (+) percent change indicates an increase in pain level and is negative for individual subject success.&#xD;
Overall study success criteria is defined as at least 65%±5% (percentage of subjects) meeting the study individual success criteria.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erchonia EVRL</title>
          <description>635 nanometers (nm) and 405 nm dual-diode laser application&#xD;
Erchonia EVRL: Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elvira Cawthon</name_or_title>
      <organization>Regulatory Insight, Inc.</organization>
      <phone>6154475150</phone>
      <email>elvira@reginsight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

